Phase 2 study of vadastuximab talirine in younger newly diagnosed acute myeloid leukemia patients

Trial Profile

Phase 2 study of vadastuximab talirine in younger newly diagnosed acute myeloid leukemia patients

Planning
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Vadastuximab talirine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2017 According to a Seattle Genetics media release, this trial is expected to start in second half of 2017.
    • 10 Dec 2016 New trial record
    • 03 Dec 2016 According to a Seattle Genetics media release, this trial is expected to start in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top